Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma | Zendy

Scott F. Huntington | Zendy; Gottfried von Keudell | Zendy; Amy J. Davidoff | Zendy; Cary P. Gross | Zendy; Sapna A. Prasad | Zendy

Open Access

Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma

Author(s) -

Scott F. Huntington,

Gottfried von Keudell,

Amy J. Davidoff,

Cary P. Gross,

Sapna A. Prasad

Publication year - 2018

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.18.00122

Subject(s) - abvd , brentuximab vedotin , dacarbazine , medicine , vinblastine , bleomycin , hodgkin's lymphoma , oncology , cost effectiveness , chemotherapy , surgery , nuclear medicine , hodgkin lymphoma , lymphoma , vincristine , risk analysis (engineering) , cyclophosphamide

Substituting BV for bleomycin during first-line therapy for stage III or IV HL is unlikely to be cost effective under current drug pricing. Should indication-specific pricing be implemented, significant price reductions for BV used in the first-line setting would be needed to reduce ICERs to more widely acceptable values.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research